Form 4: MaxCyte Executive Ali Soleymannezhad Reports Stock and Option Awards

Chief Commercial Officer Ali Soleymannezhad of MaxCyte, Inc. reports the acquisition of restricted stock units and stock options.

Summary

• On September 16, 2024, Ali Soleymannezhad, Chief Commercial Officer of MaxCyte, Inc., was granted 10,400 restricted stock units (RSUs) and options to purchase 20,800 shares of common stock.
• The RSUs vest 25% on September 16, 2025, and the remaining 75% vest in three equal annual installments thereafter, contingent upon continued service.
• The stock options vest 25% on September 16, 2025, and the remaining 75% vest in 36 substantially equal monthly installments thereafter, also contingent upon continued service.
• Following these transactions, Soleymannezhad directly owns 26,025 shares of MaxCyte common stock and options to purchase 20,800 shares.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of executive compensation. It's neutral in sentiment as it simply reports facts without expressing positive or negative views.

Positives

• The vesting schedules for both the RSUs and stock options are tied to continued service, incentivizing the executive to remain with the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders, incentivizing value creation.

Key Dates